RTO — Rentokil Initial Share Price
Last trade - 00:00- £11.80bn
- £14.93bn
- £5.38bn
- 84
- 26
- 70
- 65
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 18.07 | ||
| PEG Ratio (f) | 1.91 | ||
| EPS Growth (f) | 10.42% | ||
| Dividend Yield (f) | 2.11% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.8 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 21.77 | ||
| Price to Sales | 2.13 | ||
| EV to EBITDA | 13.25 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.31% | ||
| Return on Equity | 9.31% | ||
| Operating Margin | 11.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 2,714.4 | 2,803.3 | 2,956.6 | 3,714 | 5,375 | 5,515.65 | 5,769.95 | 16.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +58.91 | -3.65 | +34.52 | +42.3 | -3.8 | +7.73 | +13.16 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rentokil Initial plc is a United Kingdom-based company, which is engaged in pest control and hygiene and wellbeing services. The Company operates in North America, Europe, the United Kingdom, the Rest of World, Asia, and the Pacific. The Company is a commercial pest control company providing risk mitigation, reassurance and responsiveness to customers. It offers a complete range of pest control services, from rodents to flying and crawling insects, to other forms of wildlife management. It offers a range of hygiene services, including the provision and maintenance of products, such as soap and hand sanitizer dispensers, hand dryers, air care and purification, cubicle and surface sanitizers, feminine hygiene units, toilet paper dispensers and floor protection mats. Its connected devices, PestConnect, help to provide customers with a complete pest detection solution and full traceability. Its PestConnect is a remote monitoring system for rodents.
Directors
- Richard Solomons NEC (60)
- Andrew Ransom CEO (58)
- Stuart Ingall-Tombs CFO
- Mark Purcell CIO
- Gary Booker CMO
- Daragh Fagan GCN (52)
- Paul Cochrane MDR
- Alain Moffroid MDR
- John Myers MDR
- Andrew Stone MDR
- Phill Wood MDR
- Vanessa Evans DHR (51)
- Chris Hunt OTH
- Brian Webb OTH
- Sarosh Mistry NED
- Catherine Turner NED (57)
- John Pettigrew NID (52)
- Julie Southern NID (62)
- Linda Yueh NID
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 15th, 2005
- Public Since
- June 21st, 2005
- No. of Employees
- 62,900
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
- London Stock Exchange
- Shares in Issue
- 2,524,539,885
- Address
- Riverbank, CAMBERLEY, GU17 9AB,
- Web
- https://www.rentokil-initial.com/
- Phone
- +44 1276607444
- Auditors
- PricewaterhouseCoopers LLP
Latest News for RTO
Upcoming Events for RTO
Half Year 2024 Rentokil Initial PLC Earnings Release
Q3 2024 Rentokil Initial PLC Trading Statement Release
Similar to RTO
ADVFN
London Stock Exchange
Alpha Financial Markets Consulting
London Stock Exchange
Andrews Sykes
London Stock Exchange
Anexo
London Stock Exchange
Ashtead
London Stock Exchange
FAQ
As of Today at 22:56 UTC, shares in Rentokil Initial are trading at 453.50p. This share price information is delayed by 15 minutes.
Shares in Rentokil Initial last closed at 453.50p and the price had moved by -27% over the past 365 days. In terms of relative price strength the Rentokil Initial share price has underperformed the FTSE All Share Index by -34.1% over the past year.
The overall consensus recommendation for Rentokil Initial is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Rentokil Initial dividend yield is 1.91% based on the trailing twelve month period.
Last year, Rentokil Initial paid a total dividend of £0.09, and it currently has a trailing dividend yield of 1.91%. We do not have any data on when Rentokil Initial is to next pay dividends.
We do not have data on when Rentokil Initial is to next pay dividends. The historic dividend yield on Rentokil Initial shares is currently 1.91%.
To buy shares in Rentokil Initial you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 453.50p, shares in Rentokil Initial had a market capitalisation of £11.45bn.
Here are the trading details for Rentokil Initial:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: RTO
Based on an overall assessment of its quality, value and momentum Rentokil Initial is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Rentokil Initial is 520.70p. That is 14.82% above the last closing price of 453.50p.
Analysts covering Rentokil Initial currently have a consensus Earnings Per Share (EPS) forecast of £0.24 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rentokil Initial. Over the past six months, its share price has underperformed the FTSE All Share Index by -1.44%.
As of the last closing price of 453.50p, shares in Rentokil Initial were trading -0.93% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rentokil Initial PE ratio based on its reported earnings over the past 12 months is 18.07. The shares last closed at 453.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Rentokil Initial's management team is headed by:
- Richard Solomons - NEC
- Andrew Ransom - CEO
- Stuart Ingall-Tombs - CFO
- Mark Purcell - CIO
- Gary Booker - CMO
- Daragh Fagan - GCN
- Paul Cochrane - MDR
- Alain Moffroid - MDR
- John Myers - MDR
- Andrew Stone - MDR
- Phill Wood - MDR
- Vanessa Evans - DHR
- Chris Hunt - OTH
- Brian Webb - OTH
- Sarosh Mistry - NED
- Catherine Turner - NED
- John Pettigrew - NID
- Julie Southern - NID
- Linda Yueh - NID